We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | 4.91% | 2.35 | 2.30 | 2.40 | 2.30 | 2.20 | 2.20 | 1,317,704 | 16:35:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -2.02 | 7.67M |
From Apr 2023 to Apr 2024
By Kyle Morris
Shares in ImmuPharma rose 11% on Thursday after the company said it received positive guidance from the U.S. Food and Drug Administration that supports an Investigational New Drug application and a phase 2/3 adaptive clinical trial of the P140 platform for patients with chronic idiopathic demyelinating polyneuropathy.
Shares at 0850 GMT were up 0.33 pence at 3.40 pence.
The company said the FDA feedback recognised that P140 is suitable to be studied in another disease indication in addition to systemic lupus erythematosus, which supports P140 across several auto-immune/inflammatory diseases.
An IND application will now be prepared for submission to the FDA.
An application for Orphan Drug status for CIDP will be also submitted in parallel to the full IND application.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
May 18, 2023 05:23 ET (09:23 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
